TJPC(SH:600488) Zhong Zheng Wang·2025-07-29 14:25Core Viewpoint - Tianyao Pharmaceutical's subsidiary Tianyao Heping has received approval for two types of peritoneal dialysis solutions, which will enhance the company's market competitiveness in this product line [1][2]. Group 1: Product Approval and Market Impact - Tianyao Heping's peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) have passed the consistency evaluation for generic drugs, allowing them to be marketed [1]. - The domestic sales forecast for lactate-G1.5% is projected to be 1.548 billion yuan in 2023 and 1.689 billion yuan in 2024, while lactate-G2.5% is expected to generate sales of 743 million yuan in 2023 and 840 million yuan in 2024 [1]. - The approval will lead to appropriate support in medical insurance payments and priority procurement by medical institutions [1]. Group 2: Company Strategy and Development - The company is committed to an integrated development strategy of raw materials and formulations, focusing on steroid hormones and amino acid raw materials [2]. - Tianyao Pharmaceutical has made significant progress in new product research and development, consistency evaluation, and drug registration, with 32 products passing the consistency evaluation and 18 obtaining drug registration certificates [2]. - Several key formulation products have achieved annual sales exceeding 100 million yuan [2].